Sector View

Software and IT Services

Oracle Q4 FY16 results: positive read-across for European Software vendors

	1 M	3 M	6 M	31/12/15
Softw.& Comp.	-2.6%	-4.4%	-5.8%	-7.7%
DJ Stoxx 600	-4.0%	-5.8%	-10.9%	-12.2%
*Stovy Sector Indices				

Yesterday evening, Oracle reported Q4 FY16 sales (FYE 31st May) in line with expectations both on cloud SaaS/PaaS sales growth and non-GAAP EPS. FY17 outlook continues to reflect Oracle's accelerated positive momentum in the cloud, helped by an aggressive strategy. We view these numbers as a positive read-across for European software vendors.

Companies covered								
ALTEN		SELL	EUR48					
Last Price	EUR52,25	Market Cap.	EUR1,759m					
ALTRAN TECHNOLOGIES		NEUTRAL	EUR13					
Last Price	EUR11,78	Market Cap.	EUR2,071m					
ATOS		BUY	EUR93					
Last Price	EUR76,64	Market Cap.	EUR7,952m					
AXWAY SOFTWARE		NEUTRAL	EUR20					
Last Price	EUR20,25	Market Cap.	EUR421m					
CAPGEMINI		BUY	EUR97					
Last Price	EUR81,78	Market Cap.	EUR14,081m					
CAST		NEUTRAL	EUR3,6					
Last Price	EUR3,35	Market Cap.	EUR54m					
DASSAULT SYSTEMES		SELL	EUR63					
Last Price	EUR65,78	Market Cap.	EUR16,903m					
INDRA SISTEMAS		NEUTRAL	EUR10					
Last Price	EUR9,12	Market Cap.	EUR1,497m					
SAGE GROUP		SELL	555p					
Last Price	594p	Market Cap.	GBP6,412m					
SAP		NEUTRAL	EUR73					
Last Price	EUR67,33	Market Cap.	EUR82,715m					
SOFTWARE AG		BUY	EUR40					
Last Price	EUR30,695	Market Cap.	EUR2,425m					
SOPRA STERIA GROUP		BUY	EUR130					
Last Price	EUR104,9	Market Cap.	EUR2,145m					
SWORD GROUP		BUY	EUR26					
Last Price	EUR23	Market Cap.	EUR217m					
TEMENOS GR	OUP	NEUTRAL	CHF52					
Last Price	CHF53,35	Market Cap.	CHF3,709m					
		-						

ANALYSIS

- Revenues and non-GAAP EPS in line with consensus estimates. For its quarter ended 31st May 2016, Oracle has reported non-GAAP EPS up 9% (+5% at cc) at USD0.81 (i.e. USD0.82 at cc) or at the low-end of company guidance, which was given at cc (USD0.82-0.85), and in line with consensus (USD0.82). Total revenues were flat at cc to USD10.6bn or at the mid-point of the guidance range (-2%/+1% at cc) and 1% above consensus (USD10.46bn). Cloud and on-premise software revenues were up 2% at cc to USD8.44bn (guidance: +1%/+2%; consensus: USD8.37bn). Hardware product sales were down 10 % at cc.
- Q4 FY16 details. At cc, on-premise software sales were down 2%, with new licences down 10% and maintenance up 4%, cloud SaaS/PaaS sales rose up an impressive 68% (guidance: +57%/+61% at cc), and cloud laaS was up 8% (guidance: -1%/+3% at cc). Cloud and on-premise software revenues were down 2% cc (vs. +1% in Q3) in the Americas, up 5% at cc (vs. +2% in Q3) in EMEA, and up 11% at cc (vs. +13% in Q3) in Asia Pacific. In SaaS, Oracle added 1,640 new customers (vs. 942 in Q3) plus 917 customer expansions, of which 318 (vs. 213) in HCM, 700 (vs. 465) in Customer Experience and 808 (vs. 334) in ERP. Its SaaS/PaaS installed based now reaches 12,000 customers. It now has 2,600 Cloud ERP customers on the Oracle public cloud (vs. 230+ for Workday on Financial Management and 3,200 for SAP on S/4HANA including a vast majority of on-premise customers), out of which 1,577 are now live on Fusion. In PaaS, Oracle had 2,005 new customers and has an installed base of 9,000 clients.
- Q1 FY17 guidance. For Q1 FY17 (August 2016 quarter), management expects total revenues up 2-5% at cc, with Cloud & On-Premise software guidance up 5-7% at cc (SaaS/PaaS guidance +75%/+80% at cc including acquisitions vs. 'above +59% at cc'), and non-GAAP EPS USD0.56-0.60. Cloud bookings were up 52% at cc and Oracle now ambitions to be the first software company to generate USD10bn revenues in cloud subscriptions. For FY17, Oracle anticipates SaaS/PaaS revenues up above 65% (vs. +62% for FY16). NB. SaaS/PaaS posted a gross margin of 56.6% in Q4 FY16 (+17ppt), should continue to rise over FY17, and Oracle confirms its plan to reach 80% as soon as possible.
- Positive short-term read-across for European Software vendors. As such, from a short-term perspective we consider this publication is positive for SAP and other European software vendors. Revenue momentum accelerates in the cloud, and there is no longer reluctance for customers to embrace the cloud whatever the geography. However, with an aggressive strategy, Oracle's cloud SaaS/PaaS revenue growth (+68% Ifl) remains way above the cloud subscription growth of SAP (+33% Ifl in Q1 16), Workday (+39% in Q1 FY17) and Salesforce (+28% Ifl in Q1 FY17).



VALUATION

European software companies: EV/EBIT multiples of 14.8x for 2016e and 13.5x for 2017e.

NEXT CATALYSTS

- Accenture's Q3 FY16 results on 23rd June before US markets open.
- SAP's Q2 16 results on 20th July before markets open.

Click here to download document



Analyst:
Gregory Ramirez
33(0) 1 56 68 75 91
gramirez@bryangarnier.com

Sector Team : Richard-Maxime Beaudoux Thomas Coudry Dorian Terral

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY

Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

NEUTRAL

Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

SELL

Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 56,5%

NEUTRAL ratings 34%

SELL ratings 9,5%

Research Disclosure Legend

		_	
1	Bryan Garnier shareholding in Issuer	Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	No
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	
6	Investment banking agreement	A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.	
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	
13	Bryan Garnier executive is an officer		
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London			
Beaufort House			
15 St. Botolph Street			
London EC3A 7BB			
Tel: +44 (0) 207 332 2500			
Fax: +44 (0) 207 332 2559			
Authorised and regulated by the			
Financial Conduct Authority (FCA)			

Paris 26 Avenue des Champs Elysées 75008 Paris Tel: +33 (0) 1 56 68 75 00 Fax: +33 (0) 1 56 68 75 01 Regulated by the Financial Conduct Authority (FCA) and the Autorité de Contrôle prudential et de resolution (ACPR)

New York
750 Lexington Avenue
New York, NY 10022
Tel: +1 (0) 212 337 7000
Fax: +1 (0) 212 337 7002
FINRA and SIPC member

Munich Widenmayerstrasse 29 80538 Munich Germany +49 89 2422 62 11

New Delhi The Imperial Hotel Janpath New Delhi 110 001 Tel +91 11 4132 6062 +91 98 1111 5119 Fax +91 11 2621 9062 Geneva rue de Grenus 7 CP 2113 Genève 1, CH 1211 Tel +4122 731 3263 Fax+4122731 3243 Regulated by the FINMA

Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report. Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC. 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available.